用于心房动和心力衰竭患者的设备治疗,使用保存的喷射分数
Zixi Zhang1, Yichao Xiao2, Yongguo Dai3
1Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, People's Republic of China.
Heart failure reviews
|November 8, 2023
概括
设备治疗为心房动 (AF) 和心力衰竭与保留射出小部分 (HFpEF) 的患者提供了一种有前途的非药物治疗方法. 这些干预措施可以优化心脏功能,改善症状,提高生活质量.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 医疗器械 医疗器械
背景情况:
- 前庭动 (AF) 和心力衰竭与保留喷射分数 (HFpEF) 代表了复杂的心血管疾病.
- 管理患有AF和HFpEF的患者存在重大临床挑战.
- 基于非药物设备的疗法正在成为关键的进步.
研究的目的:
- 审查针对AF和HFpEF患者的基于设备的干预措施的影响.
- 强调这些设备在优化治疗策略方面的潜力.
- 确定当前的研究缺口和未来研究领域.
主要方法:
- 对AF和HFpEF的设备治疗现有文献的审查.
- 分析心脏再同步疗法 (CRT) 用他的捆或左捆-分支节奏.
- 评估新的策略,如心脏收缩度调制 (CCM) 和迷走神经刺激 (VNS).
- 对左心室 (LV) 扩展器和基于设备的心脏门干预措施 (TAVR,TEER) 的评估.
主要成果:
- 带有His-bundle/left bundle-branch节奏的CRT可以改善心脏功能和心脏同步.
- CCM和VNS显示了增强心肌收缩性和自主平衡的潜力.
- 过导管疗法 (TAVR,TEER) 减少AF负担,并改善相关患者的运动耐受性.
- LV扩展剂显示短期益处,但需要进一步的长期安全性和疗效数据,特别是在AF患者.
结论:
- 设备疗法具有显著的潜力,可以改善AF和HFpEF患者的治疗结果.
- 需要进一步的研究来完善患者选择,并确认长期的安全性和有效性.
- 优化设备选择和植入可以提高这个复杂的患者群体的生活质量.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:26Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598